Sysmex (SSMXY) Projected to Post Quarterly Earnings on Wednesday

Sysmex (OTCMKTS:SSMXY) is expected to post its resultson Wednesday, May 13th. Analysts expect Sysmex to post earnings of $0.0372 per share and revenue of $862.45 million for the quarter.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. On average, analysts expect Sysmex to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sysmex Stock Performance

OTCMKTS SSMXY opened at $8.42 on Wednesday. The company has a market cap of $5.30 billion, a P/E ratio of 17.54 and a beta of 1.10. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The business’s 50 day moving average price is $8.82 and its 200-day moving average price is $9.57. Sysmex has a fifty-two week low of $8.15 and a fifty-two week high of $19.39.

Analyst Upgrades and Downgrades

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.